{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:58:56Z","timestamp":1781326736490,"version":"3.54.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003785","name":"Guangdong Provincial Medical Research Foundation","doi-asserted-by":"publisher","award":["B2025153"],"award-info":[{"award-number":["B2025153"]}],"id":[{"id":"10.13039\/501100003785","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515012180"],"award-info":[{"award-number":["2024A1515012180"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejmech.2025.118456","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T07:53:57Z","timestamp":1764834837000},"page":"118456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis and bioevaluation of novel combretastatin A-4 based derivatives as potent tubulin\/HDAC6 dual-target inhibitors for cancer therapy"],"prefix":"10.1016","volume":"303","author":[{"given":"Zhongkai","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tangyang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9400-922X","authenticated-orcid":false,"given":"Peiliang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118456_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/or.2024.1432131","article-title":"Research progress on the mechanism of histone deacetylases in ferroptosis of glioma","volume":"18","author":"Ma","year":"2024","journal-title":"Oncol. Rev."},{"key":"10.1016\/j.ejmech.2025.118456_bib2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.7150\/ijbs.9067","article-title":"Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications","volume":"10","author":"Li","year":"2014","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ejmech.2025.118456_bib3","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118456_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116696","article-title":"Overview of class I HDAC modulators: inhibitors and degraders","volume":"276","author":"Huang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118456_bib5","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1021\/jm501941q","article-title":"Epigenetics: novel therapeutics targeting epigenetics","volume":"58","author":"Conway","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118456_bib6","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1038\/leu.2013.38","article-title":"Phase Ia\/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies","volume":"27","author":"DeAngelo","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.118456_bib7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1517\/17425255.2013.754011","article-title":"Toxicological and metabolic considerations for histone deacetylase inhibitors","volume":"9","author":"Fraczek","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejmech.2025.118456_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116571","article-title":"Advances in dual-targeting inhibitors of HDAC6 for cancer treatment","volume":"275","author":"Gu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118456_bib9","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.3390\/pharmaceutics15112581","article-title":"Targeting histone deacetylases 6 in dual-target therapy of cancer","volume":"15","author":"Beljkas","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2025.118456_bib10","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41580-020-0214-3","article-title":"The tubulin code and its role in controlling microtubule properties and functions","volume":"21","author":"Janke","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118456_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115372","article-title":"Identification of pyrrolo[3',4':3,4]cyclohepta[1,2-d][1,2]oxazoles as promising new candidates for the treatment of lymphomas","volume":"254","author":"Barreca","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118456_bib12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/14728222.2024.2341630","article-title":"An update on the development on tubulin inhibitors for the treatment of solid tumors","volume":"28","author":"Yakkala","year":"2024","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2025.118456_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.107076","article-title":"Tubulin inhibitors. Selected scaffolds and main trends in the design of novel anticancer and antiparasitic agents","volume":"143","author":"Podolak","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118456_bib14","article-title":"Leveraging tubulin isotype structural differences to design less hematotoxic beta5 selective covalent inhibitors for NSCLC","author":"Kumari","year":"2025","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118456_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114744","article-title":"Development of [1,2]oxazoloisoindoles tubulin polymerization inhibitors: further chemical modifications and potential therapeutic effects against lymphomas","volume":"243","author":"Barreca","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118456_bib16","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/1535-7163.MCT-24-1208","article-title":"RGN6024 is a brain-penetrant, small molecule tubulin destabilizer for the treatment of glioblastoma","volume":"24","author":"Patr\u00f3n","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejmech.2025.118456_bib17","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1158\/1535-7163.MCT-23-0179","article-title":"Microtubule-targeting combined with HDAC inhibition is a novel therapeutic strategy for diffuseintrinsic pontine gliomas","volume":"22","author":"Ehteda","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejmech.2025.118456_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115070","article-title":"A novel aromatic amide derivative SY-65 Co-targeted tubulin and histone deacetylase 1 with potent anticancer activity in vitro and in vivo","volume":"201","author":"Li","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118456_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117022","article-title":"Tubulin\/HDAC dual-target inhibitors: insights from design strategies, SARs, and therapeutic potential","volume":"281","author":"Zhang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118456_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113790","article-title":"Discovery of novel tubulin\/HDAC dual-target inhibitors with strong antitumor and antiangiogenic potency","volume":"225","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118456_bib21","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.1021\/acs.jmedchem.8b00050","article-title":"Design and synthesis of tubulin and histone deacetylase inhibitor based on iso-combretastatin A-4","volume":"61","author":"Lamaa","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118456_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106112","article-title":"Discovery of a 2,6-diarylpyridine-based hydroxamic acid derivative as novel histone deacetylase 8 and tubulin dual inhibitor for the treatment of neuroblastoma","volume":"128","author":"Tang","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118456_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107930","article-title":"Combretastatin A-4 based compounds as potential anticancer agents: a review","volume":"153","author":"Omar","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118456_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40661-017-0058-5","article-title":"Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management","volume":"5","author":"Grisham","year":"2018","journal-title":"Gynecol Oncol Res Pract"},{"key":"10.1016\/j.ejmech.2025.118456_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129816","article-title":"Design, concise synthesis and evaluation of novel amide-based combretastatin A-4 analogues as potent tubulin inhibitors","volume":"108","author":"Ma","year":"2024","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.118456_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108169","article-title":"A promising future for breast cancer therapy with hydroxamic acid-based histone deacetylase inhibitors","volume":"156","author":"Das","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118456_bib27","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1021\/acs.jmedchem.0c02111","article-title":"Discovery of novel pyrrolo[2,3-d]pyrimidine-based derivatives as potent JAK\/HDAC dual inhibitors for the treatment of refractory solid tumors","volume":"65","author":"Liang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118456_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117235","article-title":"Overview of the epigenetic\/cytotoxic dual-target inhibitors for cancer therapy","volume":"285","author":"Liang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118456_bib29","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1021\/acs.jmedchem.4c02441","article-title":"Structure-guided discovery of novel N4-(substituted thiazol-2-yl)-N2-(4-substituted phenyl)pyrimidine-2,4-diamines as potent CDK 2 and CDK9 dual inhibitors with high oral bioavailability","volume":"68","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118456_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.107019","article-title":"Design, synthesis, and biological evaluation of N-(pyridin-3-yl)pyrimidin-4-amine analogues as novel cyclin-dependent kinase 2 inhibitors for cancer therapy","volume":"143","author":"Zeng","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118456_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115437","article-title":"Discovery of novel 6-p-tolyl-3-(3,4,5-trimethoxybenzyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4] thiadiazine derivative as a potent tubulin inhibitor with promising in vivo antitumor activity","volume":"256","author":"Ji","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118456_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114864","article-title":"Rational design, synthesis and biological evaluation of novel 2-(substituted amino)-[1,2,4]triazolo[1,5-a]pyrimidines as novel tubulin polymerization inhibitors","volume":"244","author":"Chen","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118456_bib33","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejmech.2019.06.055","article-title":"Discovery of novel pyrimidine-based benzothiazole derivatives as potent cyclin-dependent kinase 2 inhibitors with anticancer activity","volume":"179","author":"Diao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118456_bib34","doi-asserted-by":"crossref","first-page":"8135","DOI":"10.1021\/jo015959z","article-title":"Novel syntheses of cis and trans isomers of combretastatin A-4","volume":"66","author":"Gaukroger","year":"2001","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2025.118456_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118456_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113449","article-title":"Discovery of highly potent tubulin polymerization inhibitors: design, synthesis, and structure-activity relationships of novel 2,7-diaryl-[1,2,4]triazolo[1,5-a]pyrimidines","volume":"220","author":"Huo","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118456_bib37","unstructured":"Sybyl 7.3, Tripos Inc., 1699 South Hanley Road, St. Louis, MO 63144, U.S.A."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425012218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425012218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:42:22Z","timestamp":1781325742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425012218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":37,"alternative-id":["S0223523425012218"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118456","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and bioevaluation of novel combretastatin A-4 based derivatives as potent tubulin\/HDAC6 dual-target inhibitors for cancer therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118456","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118456"}}